• Pilot and monitor the Innovation santé 2030 plan(health component of France 2030 endowed with €7.5bn): actions, research programs, funding granted to support excellence in highly innovative healthcare products, strengthen France's attractiveness, promote market access and create solid, productive and sustainable cooperations between public and private players;
• Anticipate innovations by working on healthcare foresight to define the healthcare system's future needs, anticipate their impact on the prevention and care system, how they can be integrated, and identify research priorities;
• Accelerate and transform the various existing processes to enable innovations to be made available effectively and rapidly to patients and healthcare professionals, from basic research through to dissemination (technology transfer, attractiveness of clinical research, mobilization of purchasing leverage,...);
• Support innovative and high-impact projects considered strategic; guide innovative project leaders

The Agence de l'innovation en santé has set upindividualized support for innovative project leaders, whatever their stage of development. Concrete actions have been put in place to meet the needs or difficulties encountered:

• Priority access: For treatments or technological solutions that must go through an established regulatory process;
• Outside framework: To support disruptive innovations that do not fit into the current framework (regulatory, cultural, organizational or financial) and for which adaptations are required;
• Scaling up:To enable innovations that have proven their effectiveness and usefulness for patients, the organization of care or the healthcare system, to be deployed more rapidly and competitively in France and internationally.

Whatever the level of maturity of my project.

Yes, the Agence de l'innovation en santé is piloting the health component of France 2030 and, as such, is managing planned investments via calls for projects or calls for expressions of interest.